. 2020 Feb 7;17(2):e1003033. doi: 10.1371/journal.pmed.1003033

Table 2. Unadjusted primary and secondary outcomes after 2 years’ follow-up.

Repeated PSA test	Control (n = 4,242)	Intervention (n = 3,558)	OR^a (95% CI, sign)	Intervention
Repeated PSA test	Control (n = 4,242)	Intervention (n = 3,558)	OR^a (95% CI, sign)	No genetic test (n = 2,323)	Normal genetic risk (n = 1,047)	High genetic risk (n = 136)	OR^b (95% CI)	OR^c (95% CI)
All men with a PSA test, N (%)	1,628 (38.4%)	1,218 (34.2%)	0.95 (95% CI 0.78–1.14)	833 (37.5%)	261 (24.9%)	102 (75.0%)	0.65 (95% CI 0.5–0.78)	5.96 (95% CI 3.96–8.97)
Men with an elevated PSA test, N (%)	97 (2.3%)	78 (2.2%)	1.01 (95% CI 0.71–1.43)	50 (2.2%)	16 (1.5%)	9 (6.6%)	0.71 (95% CI 0.40–1.26)	3.31 (95% CI 1.57–6.97)

^aControl versus intervention.

^bAverage risk versus no genetic test.

^cHigh risk versus no genetic test.

Abbreviations: OR, odds ratio; PSA, prostate-specific antigen